These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second-quarter earnings on Wednesday.
週三，強生公司（紐交所：JNJ）公佈了超出預期的第二季度收益。
The company posted adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion, according to data from Benzinga Pro.
據Benzinga Pro的數據顯示，該公司發佈了每股調整後的2.82美元的EPS，同比增長10.2％，超過了2.70美元的共識預期。這家制藥巨頭的銷售額爲224.5億美元，同比增長4.3％，超過了223.1億美元的共識預期。
"With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and continued expansion of newly launched products, including ACUVUE OASYS MAX 1-Day contact lenses and our VARIPULSE platform, we have a strong foundation for near and long-term growth," said Joaquin Duato, Chairman and CEO.
董事長兼首席執行官華金·杜阿託（Joaquin Duato）表示：“在強大的管道、即將到來的RYBREVANt和TREMFYA的監管里程碑、Shockwave的整合以及新推出的產品，包括ACUVUE OASYS MAX 1-Day隱形眼鏡和我們的VARIPULSE平台的持續擴展下，我們爲近期和長期的增長奠定了堅實的基礎。”
Johnson & Johnson raised fiscal year 2024 operational sales guidance to $89.2 billion-$89.6 billion versus prior guidance of $88.7 billion-$89.1 billion.
強生公司將2024財年運營銷售指引上調至892億美元-896億美元，上次指引爲887億美元-891億美元。
The company said it expects fiscal year 2024 adjusted EPS guidance of $9.97–$10.07, down from prior guidance of $10.57–$10.72 versus the consensus of $10.01, to reflect the impact of recent acquisitions of Shockwave Medical, Proteologix, and NM26 Bispecific Antibody.
該公司表示，預計2024財年調整後的EPS指引爲9.97美元-10.07美元，低於先前的10.57美元-10.72美元，以反映Shockwave Medical、Proteologix和NM26 Bispecific Antibody的最新收購對業績的影響。
Johnson & Johnson shares gained 0.1% to trade at $156.72 on Thursday.
週四，強生公司股票上漲0.1％，交易價格爲156.72美元。
These analysts made changes to their price targets on Johnson & Johnson following the announcement.
這些分析師根據公告對強生公司的價格目標進行了調整。
- Morgan Stanley analyst Terence Flynn maintained Johnson & Johnson with an Equal-Weight rating and boosted the price target from $167 to $169.
- TD Cowen analyst Joshua Jennings maintained the stock with a Buy rating, while cutting the price target from $195 to $185.
- RBC Capital analyst Shagun Singh reiterated Johnson & Johnson with an Outperform rating and maintained a price target of $175.
- 摩根士丹利分析師Terence Flynn維持強生公司的等重評級，並將價格目標從167美元上調至169美元。
- TD Cowen分析師Joshua Jennings保持買入評級，但將價格目標從195美元下調至185美元。
- RBC Capital分析師Shagun Singh重申強生公司的跑贏大盤評級，並維持175美元的價格目標。
Read This:
閱讀更多：
- PodcastOne And 2 Other Stocks Under $2 Insiders Are Buying
- PodcastOne和其他兩隻股票被內部人員買入，價格低於2美元。